YOLFTbeta
69

Acepodia, Inc.

6976 · TWO · Healthcare / Biotechnology

11.95TWD+0.05 (+0.42%)

Price History

Full chart

Market Stats

Previous Close11.90
Open11.90
Day Range11.60 – 11.95
52-Week Range10.85 – 17.50
Volume141.58K
Market Cap7.46B
P/E (TTM)0.00
Forward P/E0.00
EPS-1.42
Dividend Yield0.00%
Beta0.51
50-Day Avg12.32
200-Day Avg13.03

About

Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address cancer care. It develops AD2C targeting GPC3 for HCC which is in preclinical stage; ACE 1831 targeting CD20 that is in phase 1 clinical trial; The company is based in Grand Cayman, the Cayman Islands.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Shih-Chia Hsiao Ph.D.
  • Employees0
  • HeadquartersUgland House, Grand Cayman, Cayman Islands, KY1-1104, Taiwan
  • Websitehttps://www.acepodia.com

Leadership

  • Dr. Shih-Chia Hsiao Ph.D.Co-Founder, CEO, President & Chairman · b. 1982
  • Dr. Yuhmin Yang Ph.D.Co-Founder & Advisor · b. 1948
  • Ms. Grace ChouSenior Director of Finance
  • Mr. YanDa LaiExecutive Director of Operations
  • Ms. Yajun Wang Ph.D.Chief Technical Officer
  • Ms. Jessica Lee M.B.A., M.S.Head of Business Development
  • Dr. Arthur Foo Ph.D.Head of Clinical operation
  • Dr. Erick HuangHead of Clinical Development
  • Stephanie HsiaoSecretary

Financials

Income Statement

Currency: TWD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-0016.59M427.00K185.00K
Growth (%)-----97.43%-56.67%
Cost of Revenue---0149.00K64.00K
Gross Profit---16.59M278.00K121.00K
Gross Margin---100.00%65.11%65.41%
Operating Expense---828.29M758.18M969.32M
Operating Income-149.64M-477.29M-1.41B-811.70M-757.90M-969.20M
Operating Margin----4891.82%-177493.91%-523891.89%
EBITDA-450.61M-865.61M-1.39B-764.52M-385.83M-642.06M
EBITDA Margin----4607.48%-90359.02%-347060.00%
Net Income-454.96M-878.51M-1.41B-817.32M-496.75M-754.40M
Net Income Margin----4925.69%-116334.43%-407784.32%
R&D115.53M303.45M341.59M310.94M612.65M806.75M
R&D as % of Total Revenue---1873.92%143478.92%436083.78%
Interest Expense60.00K798.00K1.51M4.84M6.49M6.01M
Interest Expense % of Total Revenue---29.19%1520.61%3250.27%

Balance Sheet

Currency: TWD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets253.24M3.90B3.87B6.82B6.82B5.83B
Total Liabilities963.47M5.36B6.88B384.47M479.25M415.14M
Total Equity-710.23M-1.46B-3.01B6.43B6.34B5.42B
Cash225.59M1.55B3.73B6.29B5.87B3.80B
Total Debt6.95M53.81M52.41M273.81M--
Net Debt-218.64M-1.50B-3.67B-6.02B--

Cash Flow

Currency: TWD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-103.40M-357.93M-372.78M-282.72M-369.04M-707.27M
Financing Cash Flow-1.29M3.98B-9.63M3.00B--
Capital Expenditure3.62M28.66M7.71M179.37M127.79M72.91M
Free Cash Flow-107.02M-386.59M-380.49M-462.09M-496.82M-780.18M
FCF to OCF103.50%108.01%102.07%163.45%134.63%110.31%

Key Statistics & Ratios

Market Cap7.46B
Enterprise Value4.38B
Trailing P/E0.00
Forward P/E0.00
Price / Sales37318.58
Price / Book1.49
EPS-1.42
Book Value8.70
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-949.15M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-15.77%
Return on Assets-11.36%
Shares Outstanding582.87M
Shares Float298.23M
Beta0.51
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%